Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on autoimmune diseases

NCT ID NCT07155369

Ongoing Disease control Sponsor: The Affiliated Hospital of Xuzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new treatment for people with lupus or scleroderma that hasn't improved with standard care. The treatment uses specially engineered immune cells from a healthy donor (called universal CAR T-cells) to target and destroy faulty immune cells. The goal is to control the disease and reduce symptoms, not to cure it. The trial involves 18 participants and will monitor safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
UCAR-T cells (universal donor CAR T-cells targeting CD19 and BCMA) with cyclophosphamide and fludarabine
What this could lead to
If successful, this could offer a new treatment option for people with severe lupus or scleroderma that hasn't responded to other therapies, potentially putting the disease into remission.
What could go wrong
This is a very early, small trial with only 18 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC SCLEROSIS

Contacts and locations

Locations

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.